

Depressive Signs and Symptoms in Schizophrenia

A Prospective Blinded Trial of Olanzapine and Haloperidol

Gary D. Tollefson, MD, PhD; Todd M. Sanger, PhD; Yili Lu, PhD; Martha E. Thieme

Background: Depressive signs and symptoms during the course of schizophrenia are common and have been associated with impaired recovery and a higher risk of self-harm. Novel antipsychotic agents introduce new pharmacological avenues that may differentially affect schizophrenic signs and symptoms, including depression.

Methods: This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D₂ antagonist haloperidol (5-20 mg/d). Patients were evaluated with the Positive and Negative Syndrome Scale, the Montgomery-Asberg Depression Rating Scale, and the Simpson-Angus Rating Scale. The trial consisted of a 6-week and a 46-week masked responder maintenance period.

Results: At least moderate depressive signs and symptoms (Montgomery-Asberg Depression Rating Scale score, ≥ 16) were seen in slightly more than half of this sample. Although both treatments were associated with short-term baseline-to-end point improvement on the

Montgomery-Asberg Depression Rating Scale, olanzapine-associated improvements were significantly superior to those observed with haloperidol ($P = .001$). Furthermore, the response rate for the group receiving olanzapine ($\geq 50\%$ improvement on the Montgomery-Asberg Depression Rating Scale after at least 3 weeks of treatment) was also significantly higher ($P = .008$). Analysis demonstrated that improvement in positive, negative, and/or extrapyramidal symptoms was associated with mood improvement (indirect effect); however, most of the olanzapine treatment effect on mood was a primary direct effect (57%) that alone was significantly greater than that seen with haloperidol treatment ($P < .001$).

Conclusions: Depressive signs and symptoms in schizophrenia are responsive to treatment. The pleiotropic pharmacological features of olanzapine, through 1 or more non-D₂-mediated pathways, likely contribute to its superior treatment effect. Better control of the mood disorders accompanying schizophrenia holds the possibility for improved patient outcomes.

Arch Gen Psychiatry. 1998;55:250-258

SCHIZOPHRENIA IS a heterogeneous disorder with classic domains including positive, negative, and disorganized features.¹ This triad is well recognized as the primary target in contemporary treatment studies. Mood disorders are conventionally viewed as nosologically distinct from schizophrenia, yet depressive signs and symptoms (DSS), as noted by Bleuler,² are evident during the course of schizophrenia. Although comorbid DSS in schizophrenia were initially interpreted through analytic constructs of despair, denial, or loss,³ recent findings highlight that in schizophrenia they are common and often severe, pursue a distinct course, compromise functional well-being, and

adversely affect the course of recovery. It is now recognized that patients with schizophrenia with comorbid DSS also display a distinct morbidity and mortality profile, including higher rates of relapse⁴ and suicide.⁵

Siris⁶ summarized about 30 studies of DSS in schizophrenia. Estimates of DSS range from 7% to 65%, with a modal rate of 25%.^{7,8} They do not appear to be exclusively a reaction to the course of chronic schizophrenia because they are also common among patients having a first episode.⁹

The evaluation of DSS is challenging and encompasses a differential diagnosis that includes organic factors (eg, drug abuse), environmental reactions, negative symptoms, and, more importantly, ad-

From the Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind.

METHODS

This was a double-blind, controlled clinical trial comparing the use of olanzapine with that of haloperidol for up to 52 weeks of treatment.¹⁴ Eligible patients had a diagnosis based on criteria of the *DSM-III-R*¹³ of schizophrenia or schizoaffective or schizophreniform disorder and a BPRS_{0,6} (as extracted from the Positive and Negative Symptom Scale¹⁷) screening score of 18 or higher and/or intolerance to their last neuroleptic treatment. BPRS items were scored from 0 to 6. Inpatient status was not required, and patients were medically stable. No other primary Axis I diagnosis was permitted. Additional outcome instruments were the MADRS,¹⁶ the Clinical Global Impression-Severity Scale¹⁸ for efficacy, and the Simpson-Angus Scale¹⁹ and the Barnes Akathisia Scale²⁰ for safety. In addition, vital signs and laboratory analyses were screened regularly. Following a screening assessment, a minimum washout of 3 days from oral antipsychotic agents or 1 cycle from a depot neuroleptic agent was required.

All patients provided written informed consent. Randomization was 2 persons receiving olanzapine treatment to every 1 person receiving treatment with haloperidol. All study patients began taking either olanzapine or haloperidol at 5 mg/d for the first 7 study days. Thereafter, titrations by 5 mg to a maximum of 20 mg/d were permitted at the discretion of the investigator. The need for centrally acting concomitant medications was exclusionary, with the exception of benztropine mesylate (maximum of 6 mg/d) or lorazepam (maximum of 12 mg/d) as necessary for extrapyramidal syndromes or agitation. Study patients were evaluated weekly through the first 6 visits. Responders ($\geq 40\%$ improvement in BPRS score) were evaluated monthly through 52 study weeks.

In this study, a statistical software package (SAS, version 6.07, running under version 4.2) was used to perform all statistical analyses.²¹ Analysis of variance with a type III sum of squares was used to evaluate continuous data using a general linear model procedure. The model generally included terms for treatment, country,

and treatment-by-country interaction. For analysis of proportions, the Pearson χ^2 test, using a distributive procedure within SAS, was generally used for treatment comparisons. Fisher exact confidence intervals (CIs) were constructed for differences in response rates. For all analyses, main effects were tested at a 2-sided α level of .05, and treatment-by-investigator interactions were tested at an α level of .10.

All total scores from rating scales and subscales were derived from the individual items. If any of the individual items were missing, the total score was treated as missing. When a change in the last observation carried forward from baseline to end point was assessed, patients were included in the analysis only if a patient had a baseline and at least 1 postbaseline measure. Unless otherwise defined, a baseline measure was the visit at which randomized treatment began; if data were missing, the baseline measure was the initial screening observation. Unless otherwise defined, a short-term end-point measure was the last measure obtained during the initial phase (weeks 1-6 of randomized treatment).

A path analysis²² was used to determine if a differential efficacy on DSS emerged favoring the use of either olanzapine or haloperidol and to equate unexplained DSS treatment effect after covarying for presumed confounders as a primary (direct) therapeutic effect. In path analysis, the direct effect on DSS was defined as the treatment effect remaining after covarying for secondary (indirect) effects, including positive, negative, and extrapyramidal symptoms via a linear regression. Conversely, a secondary effect, eg, through positive symptoms, was the product of the coefficient of the positive symptom covariate in the above model and the treatment effect on positive symptoms. **Figure 1** and shows a "path" model illustrating the relationships between positive, negative, depressive, and extrapyramidal symptoms. Thus, the total effect on DSS was the sum of the primary and the secondary effects. This total effect was the same as the more commonly cited unadjusted treatment effect. Thus, the path analysis assumed that a direct effect on DSS represented an improvement in the core mood exclusive of secondary factors.

verse events. The existence of multiple contributors to DSS in patients with schizophrenia highlights the importance of baseline and periodic mood assessments. Despite the prevalence, severity, prognostic importance, and psychosocial consequences of DSS, relatively few treatment studies appear in the literature. With the introduction, however, of a new generation of putative antipsychotic agents exhibiting novel pharmacological properties beyond the D₂ receptor, a unique opportunity to address this issue exists.¹⁰ Each of these neurotransmitter systems has been implicated in mood disturbance.¹¹ Olanzapine exhibits pharmacological activity within these systems and, thus, is an interesting candidate to investigate for its effect on DSS.¹²

In a 17-nation, double-blind, comparator-controlled study of 1996 patients with *DSM-III-R*¹³ criteria for schizophrenia or related conditions,¹⁴ we

hypothesized that the use of the conventional D₂ antagonist haloperidol would be a less effective treatment of DSS in schizophrenia than that of olanzapine. The following additional questions were posed:

- What is the prevalence of DSS in this large multinational cohort?
- How do DSS relate to the overall psychosis, negative symptoms, extrapyramidal syndromes, and treatment outcome?
- Do certain patients experience a treatment-associated worsening of mood, and, if so, are there between-treatment differences?
- What is the role of anticholinergic or benzodiazepine drugs in the course of mood symptoms?
- Does the treatment outcome differ between patients with schizophrenia and those with schizoaffective depression?

- Is there a concordance between a Brief Psychiatric Rating Scale (BPRS)¹⁵ depression factor and scores on the Montgomery-Asberg Depression Rating Scale (MADRS)¹⁶?
- Within a treatment assignment, does the dose necessary to achieve an antipsychotic response differ based on the presence or absence of comorbid DSS?




Figure 1. Exhibit of the “path-analytic” model illustrating the relationships between positive, negative, extrapyramidal, and mood symptoms and their relative contributions to Montgomery-Asberg Depression Rating Scale score changes. The majority and a significant change is attributable to a primary or “direct” effect on mood. Asterisk indicates $P < .001$, $t = 3.645$, $df = 1, 456$.

OVERALL POPULATION AND DISPOSITION

At baseline, 1996 patients were randomly assigned to the 2 treatment arms, 1336 to receive olanzapine and 660 to receive haloperidol. A total of 1948 patients were evaluable, ie, they had at least 1 postbaseline assessment. At baseline, patient characteristics (**Table 1**) and severity of illness (**Table 2**) were comparable. The MADRS scores were collected only at baseline and the last visit at week 6 of the study. Thus, total change scores for the last-observation-carried-forward MADRS were available on 1481 patients. Most patients (95%) had histories of previous neuroleptic therapy. An analysis of patients with and without such a history revealed no substantial baseline DSS differences. Patient disposition (**Table 3**) included statistically significantly more olanzapine-treated than haloperidol-treated patients completing the 6-week study ($P < .001$).

Table 1. Patient Characteristics

Variable	Treatment Group		Total (N=1996)	P
	Olanzapine (n=1336)	Haloperidol (n=660)		
Sex, No. (%)				
Male	869 (65.0)	427 (64.7)	1296 (64.9)	.88*
Race or ethnicity, No. (%)				
White	1078 (80.7)	523 (79.2)	1601 (80.2)	.76*
African descent	138 (10.3)	81 (12.3)	219 (11.0)	
Asian	29 (2.2)	16 (2.4)	45 (2.3)	
Hispanic	56 (4.2)	27 (4.1)	83 (4.2)	
Other	35 (2.6)	13 (2.0)	48 (2.4)	
Age, y				
Mean (SD)	38.73 (11.58)	38.27 (11.13)	38.58 (11.43)	.40†
Diagnosis, No. (%)				
Schizophrenia				.95*
Catatonic	14 (1.0)	9 (1.4)	23 (1.2)	
Disorganized	81 (6.1)	39 (5.9)	120 (6.0)	
Paranoid	662 (49.6)	327 (49.5)	989 (49.5)	
Undifferentiated	288 (21.6)	138 (20.9)	426 (21.3)	
Residual	67 (5.0)	33 (5.0)	100 (5.0)	
Schizophreniform	28 (2.1)	10 (1.5)	38 (1.9)	.95*
Schizoaffective	196 (14.7)	104 (15.8)	300 (15.0)	
Schizophrenia course, No. (%)‡				
Unspecified	30 (2.7)	18 (3.3)	48 (2.9)	.74*
Chronic/subchronic	706 (63.5)	333 (61.0)	1039 (62.7)	
Chronic/subchronic with AE	368 (33.1)	193 (35.3)	561 (33.8)	
In remission	8 (0.7)	2 (0.4)	10 (0.6)	
Age at onset of psychosis, y§				
Mean (SD)	24.16 (7.90)	23.37 (6.70)	23.90 (7.53)	.03†
Length of current episode, d				
Mean (SD)	1062.78 (2226.20)	1212.66 (2435.07)	1111.55 (2296.58)	.22†
Previous episodes, No. (%)¶				
<10	939 (71.4)	442 (68.5)	1381 (70.5)	.76*
10 to <30	235 (17.9)	126 (19.5)	361 (18.4)	
≥30	141 (10.7)	77 (11.9)	218 (11.1)	

*Frequencies are analyzed using a χ^2 test.

†Means are analyzed using a type III sum of squares analysis of variance.

‡Includes only those patients with a diagnosis of schizophrenia: olanzapine, n=1112; haloperidol, n=564. AE indicates acute exacerbation.

§Olanzapine, n=1332; haloperidol, n=657.

||Olanzapine, n=1105; haloperidol, n=533.

¶Olanzapine, n=1315; haloperidol, n=645.

Table 2. Baseline Severity of Illness

Test*	Treatment Group		Total (N=1948)	P
	Olanzapine (n=1312)	Haloperidol (n=636)		
BPRS total	33.05 (10.58)	34.09 (11.03)	33.39 (10.74)	.02†
PANSS total	90.11 (19.15)	92.10 (19.99)	90.76 (19.44)	.01†
PANSS positive	21.23 (6.05)	21.53 (6.04)	21.33 (6.05)	.49†
PANSS negative	24.02 (6.83)	24.47 (7.11)	24.17 (6.92)	.07†
PANSS general psychiatric	44.85 (10.42)	46.11 (11.12)	45.26 (10.66)	.003†
CGI-S‡	4.68 (0.93)	4.73 (0.93)	4.70 (0.93)	.05†
MADRS total§	16.62 (8.87)	16.70 (8.69)	16.64 (8.82)	.55†
BPRS depression cluster	11.04 (4.89)	11.56 (5.20)	11.21 (5.00)	.03†

*BPRS indicates the Brief Psychiatric Rating Scale; PANSS, the Positive and Negative Syndrome Scale; CGI-S, the Clinical Global Impression Severity Scale; MADRS, the Montgomery-Asberg Depression Rating Scale. Data are given as mean (SD).

†Means are analyzed using a type III sum of squares analysis of variance using a general linear model procedure that included terms for investigator, treatment, and interaction.

‡Olanzapine, n=1318; haloperidol, n=640.

§Olanzapine, n=1053; haloperidol, n=428.

Table 3. Patient Disposition

Reason for Discontinuation	No. (%)			P*
	Treatment Group		Total (N=1996)	
	Olanzapine (n=1336)	Haloperidol (n=660)		
Completed study	887 (66.4)	309 (46.8)	1196 (59.9)	<.001
Adverse event	60 (4.5)	48 (7.3)	108 (5.4)	.01
Lack of efficacy	277 (20.7)	212 (32.1)	489 (24.5)	<.001
Lost to follow-up	15 (1.1)	11 (1.7)	26 (1.3)	.31
Patient decision	48 (3.6)	49 (7.4)	97 (4.9)	<.001
Criteria not met/compliance	44 (3.3)	29 (4.4)	73 (3.7)	.22
Sponsor decision	4 (0.3)	2 (0.3)	6 (0.3)	.99

*Frequencies are analyzed using a χ^2 test.

FREQUENCY OF MODERATE DEPRESSION AT BASELINE

To estimate the frequency of at least moderate DSS, the sample was stratified a priori by a baseline MADRS score of 16 or higher. By this a priori criterion, 1047 persons, or 53% of the overall sample, were at least moderately depressed (olanzapine treatment group, 694; haloperidol treatment group, 353). A secondary definition, requiring only a MADRS item 1 (apparent sadness) mood score of 2 or higher, yielded a similar prevalence estimate. Another a priori secondary definition, a cluster of BPRS "depression" items (somatic concern, anxiety, guilt feelings, depression, tension, and motor retardation), defined moderate DSS as a cluster score of 10 or higher. This definition characterized 61% of the total sample (olanzapine treatment group, 811; haloperidol treatment group, 414). This modified factor was chosen, in contrast to the more conventional BPRS anxiety-depression factor (which excludes item 6, tension, and item 13, motor retardation), to include a psychomotor continuum, a frequent part of the depressive symptom constellation.

ANTIDEPRESSANT RESPONSE

All Patients

During the initial study phase, the mean (\pm SD) modal daily dosages of olanzapine and haloperidol were approximately 13 \pm 15 mg and 12 \pm 10 mg per day, respectively. No meaningful difference was detected between the moderate-DSS and non-DSS strata.

In the present study, both agents demonstrated an improvement in the initial 6-week study phase by baseline-to-end point change on the MADRS (last observation carried forward). Olanzapine, however, exhibited a significantly greater treatment effect ($F=10.60$; $df=1, 1439$; $P=.001$) among all patients. Olanzapine-treated patients ($n=1053$) experienced a mean (\pm SD) change of -5.97 ± 8.69 in the MADRS total scores vs -3.06 ± 8.78 points for haloperidol-treated patients ($n=428$). Hence, olanzapine-treated patients had a 2.92-point greater improvement in MADRS total scores than haloperidol-treated patients (95% CI, 1.93-3.90). These differences were consistent across countries, with the results from 13 of 17 countries favoring the use of olanzapine. Within




Figure 2. The individual Montgomery-Asberg Depression Rating Scale (MADRS) item contributions to the total score change. Those with an asterisk represent significant between-treatment differences (items 1-4 and 7), which all favored olanzapine. Asterisk indicates $P < .05$, F test of treatment effect using analysis of variance.

the MADRS total score change, item 1 (apparent sadness) improvement also favored the use of olanzapine over haloperidol ($F=12.71$; $df=1, 1441$; $P < .001$). **Figure 2** illustrates that all 10 MADRS items demonstrated greater improvement with the use of olanzapine than with haloperidol. The BPRS 6-item depression cluster demonstrated a baseline-to-end point change that also significantly favored the use of olanzapine ($n=1312$; -4.11 ± 4.98) over haloperidol ($n=636$; -2.75 ± 5.11 ; $F=5.94$; $df=1, 1906$; $P=.02$), a difference of 1.35 points (95% CI, 0.89-1.82). Among the individual 6 BPRS cluster items, scores for both the depression and motor retardation items demonstrated significantly greater improvement with the use of olanzapine than with haloperidol ($F=11.85$; $df=1, 1906$; $P=.01$; $F=4.56$; $df=1, 1906$; $P=.03$, respectively). A more stringent definition of response, ie, 50% or greater improvement from the baseline MADRS total score (on those patients completing at least 3 weeks of the treatment), demonstrated a significantly higher response rate among 950 olanzapine-treated (46%) than 350 haloperidol-treated (35%) patients ($\chi^2_1=12.02$; $P=.001$). The 95% CI on the difference-in-response rates was 5% to 17%.

Weekly BPRS depression cluster scores (observed case) were analyzed (**Figure 3**). The difference between the 2 treatments significantly favored the use of olanzapine beginning at week 1 ($F=4.62$; $df=1, 1944$; $P=.03$) and throughout the remainder of the initial 6-week phase.

Depression Outcome by Stratification

When the same analyses were conducted on the MADRS score stratum of 16 or higher at baseline, the MADRS between-treatment effects were magnified to a mean (\pm SD) score of -9.69 ± 9.02 for olanzapine-treated patients ($n=538$) vs -5.66 ± 8.96 for haloperidol-treated patients ($n=229$). This treatment-effect difference of 4.03 points (95% CI, 2.64-5.42) also significantly favored the olanzapine-treated patients.




Figure 3. A plot of weekly (observed case) change between treatments on the Brief Psychiatric Rating Scale depression cluster scores. Weekly change, beginning at week 1, favored olanzapine during the 6-week phase of the study. Asterisk indicates $P < .05$, F test of treatment in analysis of variance model.

zantine-treated patients ($F=11.00$; $df=1, 725$; $P=.001$) and was about twice as large as that seen among the haloperidol-treated patients. In a conversation, Stuart Montgomery, MD (June 15, 1996), stated to one of us (G.D.T.) that a 4-point difference between 2 active therapies on the MADRS is clinically meaningful. Of note, a significant MADRS treatment benefit was also still evident in the less depressed group baseline (MADRS score, <16), favoring the use of olanzapine (-2.08 ± 6.32 ; $n=515$) over haloperidol (-0.06 ± 7.55 ; $n=199$; $F=8.63$; $df=1, 675$; $P=.003$). This difference was 2.03 points (95% CI, 0.94-3.12). Depressive response rates in both groups favored the use of olanzapine (DSS: olanzapine, 48.3%; haloperidol, 36.9%; $\chi^2_1=6.93$, $P=.008$; 95% CI difference, 2.8%-20.1%; non-DSS: olanzapine, 42.7%; haloperidol, 32.7%; $\chi^2_1=5.20$, $P=.02$, 95% CI difference, 1.2%-18.7%).

DEPRESSIVE SYMPTOM RELATIONSHIPS

The overall correlation was strongly and positively correlated between initial 6-week change scores in the last-observation-carried-forward MADRS total and the following rating scales: BPRS total, BPRS depression cluster, Positive and Negative Syndrome Scale (PANSS), positive PANSS and negative subscales (**Figure 4**).

Among patients with a predominant negative or mixed negative symptom presentation¹⁷ ($n=913$), the change in the MADRS scores with the use of olanzapine (-6.4 ± 8.9) was significantly greater than that seen with haloperidol (-3.4 ± 9.0 ; $F=8.00$; $df=1, 873$; $P=.005$). The magnitude of the change in the MADRS scores was less among patients with predominantly positive symptoms but still significantly favored the use of olanzapine (olanzapine treatment group, -5.8 ± 8.1 ; haloperidol treatment group, -2.6 ± 7.9 ; $F=7.93$; $df=1, 256$; $P=.005$).

To better assess whether the improvement in the MADRS scores was a direct effect of therapy or the product of better control of the patient's psychotic episode, a




Figure 4. The respective correlation between treatment-associated change on several rating instruments, relevant subscales, and the Montgomery-Asberg Depression Rating Scale (MADRS). All correlation values displayed are positive. BPRS indicates Brief Psychiatric Rating Scale; PANSS, Positive and Negative Symptom Scale; CGI-S, Clinical Global Impression-Severity Scale; AIMS, Abnormal Involuntary Movement Scale; and S-A, Simpson-Angus Scale.

path analysis was conducted. This analysis demonstrated that the early improvement in MADRS scores was not solely related to an antipsychotic response that was either positive-and/or negative-symptom based (Figure 1). Rather, the majority (57%) of the treatment effect was directly on depressive symptoms. This direct effect alone was significantly greater with the use of olanzapine ($t_{1456} = -3.65$, $P < .001$). When extrapyramidal syndromes, as indirect contributors to mood change, were assessed, only 13% of the difference in the MADRS scores was attributable to olanzapine's more favorable effect on these syndromes.

SCHIZOAFFECTIVE SUBGROUP

A separate analysis of schizoaffective patients with depressed mood ($n = 134$) revealed a similar benefit on mood symptoms favoring the use of olanzapine (MADRS scores change, -9.2 ± 11.2) relative to haloperidol (MADRS scores change, -2.6 ± 10.5 ; $F_{1, 116} = 9.06$; $P = .003$). After adjusting for the variation caused by the diagnostic type through an analysis of covariance, the use of olanzapine remained significantly superior to that of haloperidol on the change in MADRS scores ($F_{1, 1433} = 5.03$; $P = .03$).

EFFECT OF CONCOMITANT AGENTS

Significantly fewer olanzapine-treated (35%) than haloperidol-treated (46%) patients received 1 or more doses of benzodiazepine hydrochloride in the 2 weeks preceding their final initial-phase evaluation ($\chi^2_1 = 15.09$, $P < .001$). Among those not receiving a benzodiazepine (olanzapine treatment group, 680; haloperidol treatment group, 230), olanzapine-treated patients demonstrated greater improvement in mean (\pm SD) MADRS scores of -6.5 ± 8.3 scale points vs haloperidol's mean (\pm SD) scores of -4.0 ± 8.4 ($F = 4.25$; $df = 1, 868$; $P = .04$). Among

those receiving a benzodiazepine (olanzapine treatment group, 373; haloperidol treatment group, 198), the olanzapine-treated patients (-5.1 ± 9.3) again outperformed the haloperidol-treated patients (-2.1 ± 9.2) on total MADRS score improvement ($F = 3.77$; $df = 1, 531$; $P = .05$). When benzodiazepine use was adjusted for in the analysis of the mean change in MADRS total scores by analysis of covariance, patients treated with olanzapine continued to demonstrate a superior improvement in mood ($F = 8.10$; $df = 1, 1399$; $P = .005$).

When anticholinergic use in the 2 weeks before the final MADRS assessment was reviewed, significantly more haloperidol-treated patients (37%) than olanzapine-treated (10%) were noted to have received at least 1 dose ($\chi^2_1 = 156.53$, $P < .001$). Among the olanzapine-treated patients either with anticholinergic use ($F = 4.46$; $df = 1, 231$; $P = .04$) or without ($F = 8.07$; $df = 1, 1177$; $P = .005$), olanzapine treatment was associated with a significantly greater mean improvement in MADRS total scores than haloperidol treatment. When concomitant anticholinergic use was adjusted for, the mean change in the MADRS total score showed a superior olanzapine treatment effect ($F = 8.82$; $df = 1, 1408$; $P = .003$).

TREATMENT-ASSOCIATED WORSENING

A treatment-associated worsening of DSS was defined a priori as a 50% or more increase in the MADRS total score from baseline at any time during the initial phase. By this criterion, a significantly higher rate of treatment-associated mood worsening was seen among haloperidol-treated (13%) than olanzapine-treated (9.0%) patients ($\chi^2_1 = 6.08$, $P = .01$).

MAINTENANCE OF INITIAL TREATMENT EFFECTS

A total of 933 initial treatment responders were eligible to move into the masked extension phase (olanzapine treatment group, 718; haloperidol treatment group, 215). **Figure 5** illustrates the 52-week course of DSS among the olanzapine- and haloperidol-treated patients. This observed case plot reveals that the initial therapeutic benefits on mood from the use of olanzapine were retained during long-term maintenance. The large attrition rate that led to a small number of haloperidol-treated patients reaching the latter stages of the trial leaves the relative long-term-maintenance benefit of haloperidol unclear.

SAFETY SUMMARY

As previously reported,¹⁴ treatment with olanzapine was well tolerated, with significantly fewer olanzapine-treated patients discontinuing early because of an adverse event ($\chi^2_1 = 6.68$, $P = .01$). A detailed discussion of events has been reported previously.¹⁴

COMMENT

Aspects of this study design, size, and analyses presented several strengths relative to previous studies. Study




Figure 5. An observed case plot of Montgomery-Asberg Depression Rating Scale change during 46 weeks of additional treatment in a double-blind, extension phase. Only initial treatment responders, defined as a 40% or greater Brief Psychiatric Rating Scale improvement and at least 3 weeks of initial treatment, were eligible.

groups were comparable at baseline. Raters were unaware of the randomized treatment, minimizing bias. Among the 1996 study participants, about 1 of every 2 patients exhibited at least a moderate mood disturbance at baseline (MADRS score, ≥ 16). Given the relatively brief prestudy washout, some residual DSS from a previous therapy was possible; however, such effects should have been equally distributed between the 2 study arms.

The present trial compared 2 chemically distinct antipsychotic therapies for their respective antidepressive properties. The use of olanzapine was statistically significantly superior to that of haloperidol in the early improvement of DSS. Substantial advantages were evident on 5 of the 10 MADRS items, including core mood (items 1 and 2). While an improvement in mood was related to a change in both positive and negative symptoms, it further appeared to be a separate dimension of the schizophrenic disease.

This study incorporated reliable and validated tools for the assessment of treatment-associated changes in mood. The MADRS, initially developed from the Comprehensive Psychopathological Rating Scale,²³ has been shown to be both sensitive and reliable.^{24,25} Montgomery²⁶ previously reported that the MADRS was a valid instrument for assessing mood in patients with schizophrenia.

Despite a broad heterogeneity in methods, previous studies have confirmed the presence of DSS during the course of schizophrenia. Burrows and Norman²⁷ reported a modal rate between 25% and 50%. In the present study, the presence and severity of comorbid, nonprimary DSS were based on the MADRS total score. Slightly more than half the sample exhibited a baseline MADRS score of 16 or higher. This rate also agrees with rates obtained by Knights et al²⁸ (Present State Examination, 54%), Johnson²⁹ (Hamilton Rating Scale for Depression (24%-50%), Martin et al³⁰ (Feighner criteria, 57%), and Leff et al (Present State Examination, 45%).³¹

Several researchers³²⁻³⁶ have suggested that there is no substantial difference in the dose necessary for the control of psychosis when comparing patients with schizophrenia with or without concurrent DSS. We evaluated the mean modal daily dosages of olanzapine and haloperidol stratified by the presence of DSS (MADRS score, ≥ 16) and saw no dose difference based on the DSS.

Most conventional neuroleptic agents, as represented by haloperidol, have been the product of D₂-receptor screening programs.¹⁰ In his review, Nelson³⁷ commented, "There is considerable evidence that neuroleptics are useful in the treatment of depression." Paradoxically, however, D₂ antagonists block receptor populations throughout the brain, including frontal reward pathways.³⁸ The consequence of attenuating reward or pleasure has raised the concern that treatment with conventional neuroleptic agents could be responsible for the emergence or intensification of DSS. This phenomenon has been referred to as neuroleptic-induced dysphoria. Although DSS are described in neuroleptic-naïve schizophrenic patients having a first episode,⁹ patients receiving conventional antipsychotic drugs may have higher rates.^{39,40} Several lines of evidence suggest that neuroleptic-induced dysphoria may not encompass full criteria for a depressive disorder,⁴¹ but nonetheless may adversely affect functional well-being.^{42,43} In our investigation, the absence of a placebo arm prevented the determination of the disease-associated base rate of treatment-emergent DSS. Treatment-associated worsenings (at any time) were observed, however. The incidence was significantly more frequent among haloperidol-treated patients ($\chi^2=6.08, P=.01$).

In previous studies of DSS in schizophrenia, a reported confounding factor was the possible effect of concomitant treatments, eg, anticholinergic agents. VanPutten and May⁴⁴ reported depressive features among neuroleptic-treated patients who manifest extrapyramidal syndromes. They furthermore observed a positive mood response to anticholinergic treatment. Galdi⁴⁰ has referred to this as "pseudo-parkinsonian depression." In the present study, an analysis of concomitant treatment records did not support anticholinergic drug use as a substantial confounder.

The superior mood improvement during monotherapy with olanzapine was unexpected in light of the vast majority of previous DSS treatment studies using combination strategies (eg, neuroleptic and cyclic antidepressant). Such studies have generated mixed results^{6,27}; however, they suffered from methodologic limitations.⁶ Several better-designed studies have established that DSS are treatment responsive with a combined drug approach. Singh et al⁴⁵ studied 60 patients who received phenothiazine therapy for at least 6 weeks. Those randomly selected to receive trazodone hydrochloride (300 mg/d) outperformed their counterparts who received a placebo in mood improvement (Hamilton Rating Scale for Depression/Clinical Global Impression), but not psychosis (BPRS). Hogarty et al⁴⁶ observed that the use of desipramine hydrochloride relieved some symptoms of chronic anxiety and mood and required less frequent dose increases in patients' neuroleptic agents. Prusoff and colleagues⁴⁷ administered perphenazine

(16-48 mg/d) plus amitriptyline hydrochloride (100-200 mg/d) or placebo to 35 patients. During a 6-month follow-up, a greater improvement in depression ratings, social well-being, and overall response characterized the adjunctively treated group. In a study of 33 patients with schizophrenia or schizoaffective disorder as determined by the *Research Diagnostic Criteria for a Selected Group of Functional Disorders*,⁴⁸ Siris et al⁴⁹ added imipramine hydrochloride (150-200 mg/d) to a stable dose of fluphenazine decanoate and reported after 6 weeks that the combination was superior to placebo on clinical global and mood assessments. After 6 months of successful open treatment with imipramine (100-300 mg/d) and fluphenazine decanoate (n=24), patients underwent a blinded randomization to either continued maintenance imipramine therapy or placebo substitution. During the next year, significantly more of the placebo-assigned patients experienced either or both a DSS relapse and psychotic exacerbation. Although the present study did not use a rerandomization, the maintenance of short-term DSS improvement was also evident.

The modest augmentation benefit of the use of cyclic antidepressant medications may reflect the limits of reuptake inhibition rather than that DSS are a relatively "refractory element" of schizophrenia. Olanzapine exhibits a broad affinity for receptor sites for 5-hydroxytryptamine (5-HT)_{2A,C}, 5-HT₃, 5-HT₆, dopamine₁₋₅, muscarinic cholinergic₁₋₅, α_1 -noradrenergic, and histamine-1 receptor sites.¹² Whether 1 or more of these systems is implicated in the pathogenesis of DSS is unknown. In light of the recent interest, however, in 5-HT₂ binding sites in both depression⁵⁰ and schizophrenia,⁵¹ it is tempting to implicate this site.

Previous investigators^{44,52-58} have noted an interrelationship between changes in DSS and psychotic symptoms. In our trial, the early stabilization of psychosis (both positive and negative features) occurred in conjunction with DSS improvement. This phenomenon leads to the question of whether DSS improvement is merely a secondary phenomenon. In a recent study of DSS in patients with their first episode, Koren and colleagues⁹ reported that the change in the Hamilton Rating Scale for Depression score correlated with both the positive ($r=0.69$) and negative ($r=0.62$) schizophrenic symptom changes. These latter 2 dimensions were assessed by the Schedule for Affective Disorders and Schizophrenia and the Scale for the Assessment of Negative Symptoms, respectively. Controlling for negative symptoms "reduced but did not eliminate the correlations between extracted Hamilton Rating Scale for Depression and positive symptoms." Although correlations between positive psychotic and depressive symptoms were observed, the present path-analytic approach demonstrated that olanzapine treatment-associated benefits in mood that were due to positive symptom change accounted for only 9% of the total benefits. Conversely, positive symptom change explained most of haloperidol's benefit.

In a recent article, Sax et al⁵⁹ investigated patients with either schizophrenia or psychotic major depression. Mood symptoms correlated with anhedonia or avolition or apathy in both groups. Others have suggested a relationship between DSS and the negative

or deficit syndrome.^{60,61} Kibel et al,⁶² however, observed that 5 of 10 MADRS items (reported sadness, inner tension, reduced sleep, pessimistic thought, and suicidal thoughts) were not significantly correlated with negative symptoms. Prosser et al⁶³ reported that certain DSS (eg, activities) were correlated with the negative symptom subscale of the BPRS. In contrast, cognitive features (eg, core mood disturbance, suicidality, and guilt) were not. In our study, a positive correlation also existed between Positive and Negative Syndrome Scale-negative and MADRS symptom change; however, path analysis showed that this correlation accounted for less than 21% of the differential olanzapine advantage on the MADRS. In contrast, a significant proportion of MADRS score improvement (57%) was through a direct effect ($t_{1456}=-3.65$, $P<.001$). Thus, these analyses suggest that the olanzapine-associated improvement in DSS was not simply the negative symptom improvement. A relationship between DSS and akinesia has been previously discussed as well.⁵⁹⁻⁶³ Siris⁶ noted that neuroleptic-induced akinesia "can at times produce a rather exact phenocopy of depression." In the present study, the use of path-analytic techniques also demonstrated that only a small amount (13%) of the olanzapine-associated MADRS improvement came from an extrapyramidal syndrome advantage.

CONCLUSIONS

This study demonstrated that DSS were common in a multinational outpatient sample with schizophrenia or closely related conditions. Furthermore, the mood disturbance appeared to represent a separate dimension of schizophrenia, as previously suggested in the literature.²⁷ The baseline-to-end point change in the MADRS score provided evidence that DSS were treatment responsive. Such improvements appeared sustainable for at least 52 weeks.

Of interest, while both agents were associated with mood improvement, only olanzapine exhibited a significant direct effect on the MADRS separate from positive or negative symptom change. This difference may relate to the respective pharmacological profiles of olanzapine and haloperidol. Whereas haloperidol is a relatively selective D₂ antagonist, olanzapine exhibits nanomolar affinities for a variety of neurotransmitter receptors. To what degree one or more of these systems participate in the pathogenesis of DSS, however, awaits additional investigation.

As stated by Hogarty et al,⁴⁶ the presence of DSS coupled with a drug's adverse effects are 2 factors "that are most likely to improve clinical outcomes and are most closely associated with quality-of-life for schizophrenic patients." In both respects, innovative antipsychotic agents such as olanzapine appear to offer promise in improving clinical outcomes in schizophrenia.

Accepted for publication July 30, 1997.

Reprints: Gary D. Tollefson, MD, PhD, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 0538, Indianapolis, IN 46285.

1. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings, and mechanisms. *Arch Gen Psychiatry*. 1995;52:341-351.
2. Bleuler E. *Dementia Praecox or the Group of Schizophrenias*. New York, NY: International Universities Press; 1950.
3. McGlashan TH, Carpenter WT Jr. An investigation of the post psychotic depressive syndrome. *Am J Psychiatry*. 1976;133:14-19.
4. Birchwood M, Mason R, Macmillan F, Healy J. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. *Psychol Med*. 1993;23:387-395.
5. Roy A, Thompson R, Kennedy S. Depression in chronic schizophrenia. *Br J Psychiatry*. 1983;142:465-470.
6. Siris SG. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, eds. *Schizophrenia*. Oxford, England: Blackwell Science Ltd; 1995:128-145.
7. Hirsch SR, Jolley AG. The dysphoric syndrome in schizophrenia and its implications for relapse. *Br J Psychiatry*. 1989;155(suppl 5):46-50.
8. Johnson DAW. The significance of depression in the prediction of relapse in chronic schizophrenia. *Br J Psychiatry*. 1988;152:320-323.
9. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. *Am J Psychiatry*. 1993;150:1643-1648.
10. Pickar D. Prospects for pharmacotherapy of schizophrenia. *Lancet*. 1995;345(8949):557-562.
11. Hyman S. How antidepressants might work. *Prog Notes*. 1995;6:11-15.
12. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. *Neuropsychopharmacology*. 1996;14:87-96.
13. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised*. Washington, DC: American Psychiatric Association; 1987.
14. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. *Am J Psychiatry*. 1997;154:457-465.
15. Overall JE, Gorham DR. Brief Psychiatric Rating Scale (BPRS). *Psychol Rep*. 1962;10:799-812.
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry*. 1979;134:382-389.
17. Kay SR, Opler LA, Fiszbein A. *Positive and Negative Syndrome Scale (PANSS) Manual*. North Tonawanda, NY: Multi-Health Systems, Inc; 1986.
18. Guy W. *ECDEU Assessment Manual for Psychopharmacology*. Bethesda, Md: US Dept of Health, Education and Welfare; 1976.
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. *Acta Psychiatr Scand*. 1970;212(suppl):11-19.
20. Barnes TR. A rating scale for drug-induced akathisia. *Br J Psychiatry*. 1989;154:672-676.
21. SAS Institute Inc. *SAS/STAT User's Guide*. Vol 1 & 2. 4th ed, 6th version. Cary, NC: SAS Institute Inc; 1990.
22. Retherford RD, Kim Choe M. Path analysis. In: *Statistical Models for Causal Analysis*. New York, NY: John Wiley & Sons Inc; 1993:93-99.
23. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. *Acta Psychiatr Scand*. 1978;271(suppl):5-27.
24. Snaith P. What do depression rating scales measure? *Br J Psychiatry*. 1993;163:293-298.
25. Galinowski A, Lehert P. Structural validity of MADRS during antidepressant treatment. *Int Clin Psychopharmacol*. 1995;10:157-161.
26. Montgomery SM. Depressive symptoms in acute schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 1979;3:429-433.
27. Burrows GD, Norman TR. Affective mood disturbance in schizophrenia. In: Ancill R, ed. *Schizophrenia: Exploring the Spectrum of Psychosis*. West Sussex, England: John Wiley & Sons Ltd; 1994:205-214.
28. Knights A, Okasha MS, Salih MA, Hirsch SR. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. *Br J Psychiatry*. 1979;135:515-523.
29. Johnson DAW. Depressions in schizophrenia: some observations on prevalence, etiology, and treatment. *Acta Psychiatr Scand*. 1981;63(suppl 291):137-144.
30. Martin RL, Cloninger RC, Guze SB, Clayton PJ. Frequency and differential diagnosis of depressive syndromes in schizophrenia. *J Clin Psychiatry*. 1985;46:9-13.
31. Leff J, Tress K, Edwards B. The clinical course of depressive symptoms in schizophrenia. *Schizophr Res*. 1988;1:25-30.
32. Roy A. Do neuroleptics cause depression? *Biol Psychiatry*. 1984;19:777-781.
33. Berrios GE, Bulbena A. Postpsychotic depression: the Fulburn cohort. *Acta Psychiatr Scand*. 1987;76:89-93.
34. Siris SG, Strahan A, Mandeli J, Cooper TB, Casey E. Fluphenazine decanoate dose and severity of depression in patients with postpsychotic depression. *Schizophr Res*. 1988;1:31-35.
35. Barnes TR, Curson DA, Liddle PF, Patel M. The nature and prevalence of depression in chronic schizophrenic in-patients. *Br J Psychiatry*. 1989;154:486-491.
36. Bandelow B, Muller P, Gaebel W, Kopcke W, Linden M, Muller-Spahn F, Pietzcker A, Reischies FM, Tegeler J. Depressive syndromes in schizophrenic patients after discharge from hospital. *Eur Arch Psychiatry Clin Neurosci*. 1990;240:113-120.
37. Nelson JC. The use of antipsychotic drugs in the treatment of depression. In: Belmaker RH, ed. *Treatment-Resistant Depression*. Costa Mesa, Calif: PMA Publishing Corp; 1987:131-146.
38. Roy A, Thompson R, Kennedy S. Depression in chronic schizophrenia. *Br J Psychiatry*. 1983;142:465-470.
39. Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? *Schizophr Bull*. 1994;20:327-338.
40. Galdi J. The causality of depression in schizophrenia. *Br J Psychiatry*. 1983;142:621-625.
41. Galdi J, Rieder RO, Silber D, Bonato RR. Genetic factors in the response to neuroleptics in schizophrenia: a pharmacogenetic study. *Psychol Med*. 1981;11:713-728.
42. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. *Schizophr Bull*. 1991;17:75-98.
43. Glazer W, Prusoff B, John K. Depression and social adjustment among chronic schizophrenic outpatients. *J Nerv Ment Dis*. 1981;169:712-717.
44. VanPutten T, May PRA. 'Akinetic depression' in schizophrenia. *Arch Gen Psychiatry*. 1978;35:1101-1107.
45. Singh AN, Saxena B, Nelson HL. A controlled clinical study of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology. *Curr Ther Res*. 1978;23:485-501.
46. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J. Pharmacotherapy of impaired affect in recovering schizophrenic patients. *Arch Gen Psychiatry*. 1995;52:29-41.
47. Prusoff BA, Williams DH, Weissman MM, Astrachan BM. Treatment of secondary depression in schizophrenia. *Arch Gen Psychiatry*. 1979;36:569-575.
48. Spitzer RL, Endicott J, Robins E. *Research Diagnostic Criteria for a Selected Group of Functional Disorders*. 3rd ed. New York, NY: Biometrics Research Division, New York State Psychiatric Institute; 1977.
49. Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB. Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial. *Arch Gen Psychiatry*. 1987;44:533-539.
50. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM. Platelet serotonin-2 receptor binding sites in depression and suicide. *Biol Psychiatry*. 1990;28:215-222.
51. Kahn RS, Davidson M. Serotonin, dopamine and their interactions in schizophrenia: an editorial. *Psychopharmacology*. 1993;112(suppl):S1-S4.
52. Rifkin A, Quitkin F, Klein D. Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. *Arch Gen Psychiatry*. 1975;32:672-674.
53. Rifkin A, Quitkin F, Kane J, Klein DF. Are prophylactic antiparkinsonian drugs necessary? a controlled study of procyclidine withdrawal. *Arch Gen Psychiatry*. 1978;35:483-489.
54. Siris SG. Akinesia and postpsychotic depression: a difficult differential diagnosis. *J Clin Psychiatry*. 1987;48:240-243.
55. Bermanzohn PC, Siris SG. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. *Compr Psychiatry*. 1992;33:221-232.
56. Möller HJ, vonZerssen D. Depressive states occurring during the neuroleptic treatment of schizophrenia. *Schizophr Bull*. 1982;8:109-117.
57. Sands JR, Harrow M. Psychotic unipolar depression at follow-up: factors related to psychosis in the affective disorders. *Am J Psychiatry*. 1994;151:995-1000.
58. Dollfus S, Petit M, Menard JF. Relationship between depressive and positive symptoms in schizophrenia. *J Affect Dis*. 1993;28:61-69.
59. Sax KW, Strakowski SM, Keck PE Jr, Upadhyaya VH, West SA, McElroy SL. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. *Br J Psychiatry*. 1996;168:68-71.
60. Whiteford HA, Riney SJ, Csernansky JG. Distinguishing depressive and negative symptoms in chronic schizophrenia. *Psychopathology*. 1976;20:234-236.
61. Kitamura T, Suga R. Depressive and negative symptoms in major psychiatric disorders. *Compr Psychiatry*. 1991;32:88-94.
62. Kibel DA, Laffont I, Liddle PF. The composition of the negative syndrome of chronic schizophrenia. *Br J Psychiatry*. 1993;162:744-750.
63. Prosser ES, Csernansky JG, Kaplan J, Thiemann S, Becker TJ, Hollister LE. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. *J Nerv Ment Dis*. 1987;175:100-105.

We thank Andrea F. DiMartini, MD, and David A. Brent, MD, for comments and encouragement and Nona DeRenzo for editorial assistance.

1. Trzepacz PT, DiMartini A, Tringali R. Psychopharmacological issues in organ transplantation, part 1: pharmacokinetics in organ failure and psychiatric aspects of immunosuppressants and anti-infectious agents. *Psychosomatics*. 1993;32:199-207.
2. Trzepacz PT, DiMartini A, Tringali R. Psychopharmacological issues in organ transplantation, part 2: psychopharmacological medications. *Psychosomatics*. 1993;34:290-298.
3. Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P-450IIIa activity in determining dosage and blood levels of FK506 and cyclosporine in liver transplant recipients. *Hepatology*. 1994;20:309-316.
4. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. *Drug Safety*. 1997;16:267-278.
5. DiMartini AF, Trzepacz PT, Davis SR. Prospective study of FK506 side effects: anxiety or akathisia? *Biol Psychiatry*. 1996;40:407-411.
6. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines, III: a pharmacokinetic interaction study with alprazolam. *J Clin Psychopharmacol*. 1995;15:399-408.
7. Barhaiya RH, Shukla UA, Kroboth PD. Coadministration of nefazodone and

- benzodiazepines, II: a pharmacokinetic interaction study with triazolam. *J Clin Psychopharmacol*. 1995;15:320-326.
8. Ashton AK, Wolin RE. Nefazodone-induced carbamazepine toxicity [letter]. *Am J Psychiatry*. 1996;153:733.
9. Marino MR, Langenbacher KM, Uderman HD. Interaction of nefazodone (N) and fluoxetine (F) [abstract]. *Clin Pharmacol Ther*. 1996;59:180.
10. Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. *Drugs*. 1997;53:608-636.
11. Helms-Smith KM, Curtis SL, Hatton RC. Apparent interaction between nefazodone and cyclosporine. *Ann Intern Med*. 1996;125:424.
12. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. *Int Clin Psychopharmacol*. 1996;11:31-61.
13. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and oxidative drug metabolism. *Clin Pharmacokinetics*. 1997;32(suppl):1-21.
14. Preskorn SH, Alderman J, Greenblatt DJ, Horst WD. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. *Psychopharmacol Bull*. 1997;33:659-665.
15. Strouse TB, Fairbanks LA, Skotzko CE, Fawzy FL. Fluoxetine and cyclosporine in organ transplantation: failure to detect significant drug interactions or adverse clinical events in depressed organ recipients. *Psychosomatics*. 1996;37:23-30.

Correction

Error in Figure. In the article titled "Depressive Signs and Symptoms in Schizophrenia: A Prospective Blinded Trial of Olanzapine and Haloperidol," published in the March 1998 issue of the ARCHIVES (1998;55:250-258), an error appeared in Figure 2 on page 254. The bars for olanzapine and haloperidol should have been separated, the lighter bar representing haloperidol-associated change, and the darker bar, olanzapine-associated change. Figure 2 is reprinted correctly here.




Figure 2. The individual Montgomery-Asberg Depression Rating Scale (MADRS) item contributions to the total score change. Those with an asterisk represent significant between-treatment differences (items 1-4 and 7), which all favored olanzapine. Asterisk indicates $P < .05$, F test of treatment effect using analysis of variance.